Marybeth S Hughes1, Winifred M Lo2, Tatiana Beresnev2, Maria Merino3, Yvonne Shutack2, R Taylor Ripley2, Jonathan M Hernandez2, Jeremy L Davis4. 1. Department of Surgery, Eastern Virginia Medical School, Norfolk, Virginia. 2. Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute, Bethesda, Maryland. 3. Translational Surgical Pathology Section, National Cancer Institute, Bethesda, Maryland. 4. Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute, Bethesda, Maryland. Electronic address: jeremy.davis@nih.gov.
Abstract
BACKGROUND: Recurrent adrenocortical carcinoma (ACC) is an aggressive disease with few options offering durable survival benefit. Despite metastasectomy, recurrence is common. Cytoreduction and intraperitoneal chemotherapy have offered improved survival in other advanced cancers. We sought to evaluate the use of cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of recurrent intraperitoneal ACC. METHODS: A phase II, single institution clinical trial was approved for patients with radiographic evidence of resectable ACC limited to the peritoneum. Patients underwent treatment if optimal cytoreduction was deemed possible at exploratory laparotomy. Primary outcome was intraperitoneal progression-free survival. Secondary outcomes were treatment-related morbidities and overall survival. RESULTS: Sixty-three patients were evaluated, of whom 11 met eligibility criteria. Nine patients underwent cytoreduction and HIPEC, including one patient who recurred and was re-treated (n = 10 treatments). One patient could not be optimally cytoreduced for HIPEC and therefore did not receive intraperitoneal chemotherapy. There was no perioperative mortality; perioperative comorbidities were limited to Clavien-Dindo grade 2 or 3 and included hematologic, infectious, and neurologic complications. Seven patients experienced disease recurrence and two patients died of disease during follow-up (median 24 mo). Intraperitoneal progression-free survival was 19 mo, and median overall survival has not yet been reached. CONCLUSIONS: Cytoreduction and HIPEC can be performed safely in selected patients. Patients with recurrent ACC confined to the peritoneal cavity can be considered for regional therapy in experienced hands. However, disease recurrence is common, and other treatment options should be explored. Published by Elsevier Inc.
BACKGROUND: Recurrent adrenocortical carcinoma (ACC) is an aggressive disease with few options offering durable survival benefit. Despite metastasectomy, recurrence is common. Cytoreduction and intraperitoneal chemotherapy have offered improved survival in other advanced cancers. We sought to evaluate the use of cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of recurrent intraperitoneal ACC. METHODS: A phase II, single institution clinical trial was approved for patients with radiographic evidence of resectable ACC limited to the peritoneum. Patients underwent treatment if optimal cytoreduction was deemed possible at exploratory laparotomy. Primary outcome was intraperitoneal progression-free survival. Secondary outcomes were treatment-related morbidities and overall survival. RESULTS: Sixty-three patients were evaluated, of whom 11 met eligibility criteria. Nine patients underwent cytoreduction and HIPEC, including one patient who recurred and was re-treated (n = 10 treatments). One patient could not be optimally cytoreduced for HIPEC and therefore did not receive intraperitoneal chemotherapy. There was no perioperative mortality; perioperative comorbidities were limited to Clavien-Dindo grade 2 or 3 and included hematologic, infectious, and neurologic complications. Seven patients experienced disease recurrence and two patientsdied of disease during follow-up (median 24 mo). Intraperitoneal progression-free survival was 19 mo, and median overall survival has not yet been reached. CONCLUSIONS: Cytoreduction and HIPEC can be performed safely in selected patients. Patients with recurrent ACC confined to the peritoneal cavity can be considered for regional therapy in experienced hands. However, disease recurrence is common, and other treatment options should be explored. Published by Elsevier Inc.
Authors: André P Fay; Aymen Elfiky; Gabriela H Teló; Rana R McKay; Marina Kaymakcalan; Paul L Nguyen; Anand Vaidya; Daniel T Ruan; Joaquim Bellmunt; Toni K Choueiri Journal: Crit Rev Oncol Hematol Date: 2014-06-04 Impact factor: 6.312
Authors: Eden C Payabyab; Sanjeeve Balasubramaniam; Maureen Edgerly; Margarita Velarde; Maria J Merino; Aradhana M Venkatesan; Harshraj Leuva; Thomas Litman; Susan E Bates; Tito Fojo Journal: Clin Cancer Res Date: 2016-10-15 Impact factor: 12.531
Authors: Chukwuemeka U Ihemelandu; Richard McQuellon; Perry Shen; John H Stewart; Konstantinos Votanopoulos; Edward A Levine Journal: Ann Surg Oncol Date: 2013-06-08 Impact factor: 5.344
Authors: R Bellantone; A Ferrante; M Boscherini; C P Lombardi; P Crucitti; F Crucitti; G Favia; D Borrelli; L Boffi; L Capussotti; G Carbone; M Casaccia; A Cavallaro; A Del Gaudio; G Dettori; V Di Giovanni; A Mazziotti; D Marrano; E Masenti; P Miccoli; F Mosca; A Mussa; R Petronio; G Piat; L Marazano Journal: Surgery Date: 1997-12 Impact factor: 3.982
Authors: Ilknur Erdogan; Timo Deutschbein; Christian Jurowich; Matthias Kroiss; Christina Ronchi; Marcus Quinkler; Jens Waldmann; Holger S Willenberg; Felix Beuschlein; Christian Fottner; Silke Klose; Anke Heidemeier; David Brix; Wiebke Fenske; Stefanie Hahner; Joachim Reibetanz; Bruno Allolio; Martin Fassnacht Journal: J Clin Endocrinol Metab Date: 2012-11-12 Impact factor: 5.958
Authors: Karl Y Bilimoria; Wen T Shen; Dina Elaraj; David J Bentrem; David J Winchester; Electron Kebebew; Cord Sturgeon Journal: Cancer Date: 2008-12-01 Impact factor: 6.860
Authors: Johannes Baur; Tjark-Ole Büntemeyer; Felix Megerle; Timo Deutschbein; Christine Spitzweg; Marcus Quinkler; Peter Nawroth; Matthias Kroiss; Christoph-Thomas Germer; Martin Fassnacht; Ulrich Steger Journal: BMC Cancer Date: 2017-08-04 Impact factor: 4.430
Authors: Lekha Madhavan Nair; K M Jagathnath Krishna; Aswin Kumar; Susan Mathews; John Joseph; Francis Vadakkumparambil James Journal: Indian J Urol Date: 2019 Jul-Sep